{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T23:51:46Z","timestamp":1774050706042,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s00277-023-05308-0","type":"journal-article","created":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T05:02:12Z","timestamp":1688187732000},"page":"2233-2240","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Busulfan plus melphalan versus high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma with high-risk features (KMM 2015)"],"prefix":"10.1007","volume":"102","author":[{"given":"Mihee","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Je-Jung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Ki","family":"Min","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Yun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-Cheol","family":"Jo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Soo","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Nam","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Rok","family":"Do","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kihyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwai Han","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Hwa","family":"Bae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun Ho","family":"Yi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jongheon","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyeon-Seok","family":"Eom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Hoon","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,1]]},"reference":[{"issue":"2","key":"5308_CR1","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1177\/2040620716680548","volume":"8","author":"S Raza","year":"2017","unstructured":"Raza S, Safyan RA, Rosenbaum E, Bowman AS, Lentzsch S (2017) Optimizing current and emerging therapies in multiple myeloma: a guide for the hematologist. Ther Adv Hematol 8(2):55\u201370","journal-title":"Ther Adv Hematol"},{"issue":"5","key":"5308_CR2","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1182\/blood-2007-08-104984","volume":"111","author":"H Brenner","year":"2008","unstructured":"Brenner H, Gondos A, Pulte D (2008) Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 111(5):2521\u20132526","journal-title":"Blood"},{"issue":"1","key":"5308_CR3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1080\/10428190210194","volume":"43","author":"JJ Lahuerta","year":"2002","unstructured":"Lahuerta JJ, Grande C, Blade J, Mart\u00ednez-L\u00f3pez J, de la Serna J, Alegre A, Garcia LJ, Caballero D, de la Rubia J, Mar\u00edn J et al (2002) Myeloablative treatments for multiple myeloma: update of a comparative study of different regimens used in patients from the Spanish registry for transplantation in multiple myeloma. Leuk Lymphoma 43(1):67\u201374","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"5308_CR4","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/sj.thj.6200369","volume":"5","author":"R Ria","year":"2004","unstructured":"Ria R, Falzetti F, Ballanti S, Minelli O, Di Ianni M, Cimminiello M, Vacca A, Dammacco F, Martelli MF, Tabilio A (2004) Melphalan versus melphalan plus busulphan in conditioning to autologous stem cell transplantation for low-risk multiple myeloma. Hematol J 5(2):118\u2013122","journal-title":"Hematol J"},{"issue":"15","key":"5308_CR5","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1200\/JCO.2009.25.4250","volume":"28","author":"AA Chanan-Khan","year":"2010","unstructured":"Chanan-Khan AA, Giralt S (2010) Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol 28(15):2612\u20132624","journal-title":"J Clin Oncol"},{"issue":"3","key":"5308_CR6","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1038\/leu.2013.335","volume":"28","author":"AK Nooka","year":"2014","unstructured":"Nooka AK, Kaufman JL, Muppidi S, Langston A, Heffner LT, Gleason C, Casbourne D, Saxe D, Boise LH, Lonial S (2014) Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients. Leukemia 28(3):690\u2013693","journal-title":"Leukemia"},{"issue":"14","key":"5308_CR7","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","volume":"376","author":"M Attal","year":"2017","unstructured":"Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, Arnulf B, Macro M, Belhadj K, Garderet L et al (2017) Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. N Engl J Med 376(14):1311\u20131320","journal-title":"N Engl J Med"},{"issue":"10068","key":"5308_CR8","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","volume":"389","author":"BGM Durie","year":"2017","unstructured":"Durie BGM, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP, Thakuri M, Reu F, Reynolds CM, Sexton R et al (2017) Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 389(10068):519\u2013527","journal-title":"Lancet"},{"issue":"8","key":"5308_CR9","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/ajh.26590","volume":"97","author":"SV Rajkumar","year":"2022","unstructured":"Rajkumar SV (2022) Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. American Journal of Hematology 97(8):1086\u20131107","journal-title":"American Journal of Hematology"},{"issue":"1","key":"5308_CR10","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1182\/blood-2009-06-229658","volume":"115","author":"M Roussel","year":"2010","unstructured":"Roussel M, Moreau P, Huynh A, Mary JY, Danho C, Caillot D, Hulin C, Fruchart C, Marit G, P\u00e9gouri\u00e9 B et al (2010) Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM). Blood 115(1):32\u201337","journal-title":"Blood"},{"issue":"5","key":"5308_CR11","doi-asserted-by":"publisher","first-page":"e266","DOI":"10.1016\/S2352-3026(19)30023-7","volume":"6","author":"Q Bashir","year":"2019","unstructured":"Bashir Q, Thall PF, Milton DR, Fox PS, Kawedia JD, Kebriaei P, Shah N, Patel K, Andersson BS, Nieto YL et al (2019) Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial. Lancet Haematol 6(5):e266\u2013e275","journal-title":"Lancet Haematol"},{"issue":"18","key":"5308_CR12","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1182\/blood.2021014635","volume":"139","author":"M Roussel","year":"2022","unstructured":"Roussel M, Lauwers-Cances V, Macro M, Leleu X, Royer B, Hulin C, Karlin L, Perrot A, Touzeau C, Chr\u00e9tien ML et al (2022) Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study. Blood 139(18):2747\u20132757","journal-title":"Blood"},{"issue":"19","key":"5308_CR13","doi-asserted-by":"publisher","first-page":"4834","DOI":"10.1182\/bloodadvances.2020002590","volume":"4","author":"N Saini","year":"2020","unstructured":"Saini N, Bashir Q, Milton DR, Tang G, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P et al (2020) Busulfan and melphalan conditioning is superior to melphalan alone in autologous stem cell transplantation for high-risk MM. Blood Adv 4(19):4834\u20134837","journal-title":"Blood Adv"},{"issue":"3","key":"5308_CR14","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s00277-005-0040-x","volume":"85","author":"PS Haas","year":"2006","unstructured":"Haas PS, Bauchm\u00fcller K, K\u00fchnemund A, Finke J, Ihorst G, Engelhardt M (2006) Efficacy of diverse high-dose regimens followed by autologous peripheral blood stem cell transplantation in consecutive multiple myeloma patients: a single-centre analysis over a 12-year period. Ann Hematol 85(3):191\u2013193","journal-title":"Ann Hematol"},{"key":"5308_CR15","doi-asserted-by":"publisher","first-page":"959949","DOI":"10.3389\/fonc.2022.959949","volume":"12","author":"GY Song","year":"2022","unstructured":"Song GY, Jung SH, Kim JS, Eom HS, Moon JH, Yhim HY, Kim K, Min CK, Lee JJ (2022) Busulfan and thiotepa as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-1801 study). Front Oncol 12:959949","journal-title":"Front Oncol"},{"issue":"7","key":"5308_CR16","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/j.bbmt.2019.03.016","volume":"25","author":"SS Park","year":"2019","unstructured":"Park SS, Kim K, Kim SJ, Lee JH, Yoon SS, Mun YC, Lee JJ, Eom HS, Kim JS, Min CK (2019) A Phase I\/II, Open-Label, Prospective, Multicenter Study to Evaluate the Efficacy and Safety of Lower Doses of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients with Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation: The KMM103 Study. Biol Blood Marrow Transplant 25(7):1312\u20131319","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"5308_CR17","doi-asserted-by":"publisher","first-page":"e283","DOI":"10.1016\/S2352-3026(17)30080-7","volume":"4","author":"Y Nieto","year":"2017","unstructured":"Nieto Y, Valdez BC, Pingali SR, Bassett R, Delgado R, Nguyen J, Shah N, Popat U, Jones RB, Andersson BS et al (2017) High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan. Lancet Haematol 4(6):e283\u2013e292","journal-title":"Lancet Haematol"},{"issue":"3","key":"5308_CR18","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/bmt.2008.446","volume":"44","author":"G Talamo","year":"2009","unstructured":"Talamo G, Claxton DF, Dougherty DW, Ehmann CW, Sivik J, Drabick JJ, Rybka W (2009) BU and CY as conditioning regimen for autologous transplant in patients with multiple myeloma. Bone Marrow Transplant 44(3):157\u2013161","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"5308_CR19","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1016\/j.bbmt.2012.03.010","volume":"18","author":"MH Abidi","year":"2012","unstructured":"Abidi MH, Agarwal R, Ayash L, Deol A, Al-Kadhimi Z, Abrams J, Cronin S, Ventimiglia M, Lum L, Zonder J et al (2012) Melphalan 180 mg\/m2 can be safely administered as conditioning regimen before an autologous stem cell transplantation (ASCT) in multiple myeloma patients with creatinine clearance 60 mL\/min\/1.73 m2 or lower with use of palifermin for cytoprotection: results of a phase I trial. Biol Blood Marrow Transplant 18(9):1455\u20131461","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"5308_CR20","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.bbmt.2012.08.009","volume":"19","author":"M Blanes","year":"2013","unstructured":"Blanes M, Lahuerta JJ, Gonz\u00e1lez JD, Ribas P, Solano C, Alegre A, Blad\u00e9 J, San Miguel JF, Sanz MA, de la Rubia J (2013) Intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-only approach. Biol Blood Marrow Transplant 19(1):69\u201374","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"5308_CR21","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1182\/blood.V99.3.731","volume":"99","author":"P Moreau","year":"2002","unstructured":"Moreau P, Facon T, Attal M, Hulin C, Michallet M, Maloisel F, Sotto JJ, Guilhot F, Marit G, Doyen C et al (2002) Comparison of 200 mg\/m(2) melphalan and 8 Gy total body irradiation plus 140 mg\/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du My\u00e9lome 9502 randomized trial. Blood 99(3):731\u2013735","journal-title":"Blood"},{"issue":"18","key":"5308_CR22","doi-asserted-by":"publisher","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","volume":"117","author":"SV Rajkumar","year":"2011","unstructured":"Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R, Blade J, Richardson P, Orlowski R, Siegel D et al (2011) Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 117(18):4691\u20134695","journal-title":"Blood"},{"key":"5308_CR23","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.blre.2019.04.002","volume":"36","author":"S Sevcikova","year":"2019","unstructured":"Sevcikova S, Minarik J, Stork M, Jelinek T, Pour L, Hajek R (2019) Extramedullary disease in multiple myeloma - controversies and future directions. Blood Rev 36:32\u201339","journal-title":"Blood Rev"},{"issue":"3","key":"5308_CR24","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant 48(3):452\u2013458","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"5308_CR25","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1182\/hematology.2021000229","volume":"2021","author":"MV Mateos","year":"2021","unstructured":"Mateos MV, Mart\u00ednez BP, Gonz\u00e1lez-Calle V (2021) High-risk multiple myeloma: how to treat at diagnosis and relapse? Hematology Am Soc Hematol Educ Program 2021(1):30\u201336","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"24","key":"5308_CR26","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","volume":"127","author":"P Sonneveld","year":"2016","unstructured":"Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC, Chng WJ, Moreau P, Attal M, Kyle RA et al (2016) Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood 127(24):2955\u20132962","journal-title":"Blood"},{"issue":"29","key":"5308_CR27","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1200\/JCO.21.02614","volume":"40","author":"M D'Agostino","year":"2022","unstructured":"D'Agostino M, Cairns DA, Lahuerta JJ, Wester R, Bertsch U, Waage A, Zamagni E, Mateos M-V, Dall'Olio D, Van De Donk NW et al (2022) Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project. J Clin Oncol 40(29):3406\u20133418","journal-title":"J Clin Oncol"},{"issue":"1","key":"5308_CR28","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00277-016-2847-z","volume":"96","author":"S Mangiacavalli","year":"2017","unstructured":"Mangiacavalli S, Pompa A, Ferretti V, Klersy C, Cocito F, Varettoni M, Cartia CS, Cazzola M, Corso A (2017) The possible role of burden of therapy on the risk of myeloma extramedullary spread. Ann Hematol 96(1):73\u201380","journal-title":"Ann Hematol"},{"issue":"2","key":"5308_CR29","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.bbmt.2014.10.023","volume":"21","author":"R Vij","year":"2015","unstructured":"Vij R, Kumar S, Zhang MJ, Zhong X, Huang J, Dispenzieri A, Abidi MH, Bird JM, Freytes CO, Gale RP et al (2015) Impact of pretransplant therapy and depth of disease response before autologous transplantation for multiple myeloma. Biol Blood Marrow Transplant 21(2):335\u2013341","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"5308_CR30","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1046\/j.1365-2141.2000.01979.x","volume":"109","author":"JJ Lahuerta","year":"2000","unstructured":"Lahuerta JJ, Martinez-Lopez J, Grande C, Blad\u00e9 J, Serna JDL, Alegre A, Garc\u00eda-Lara\u00f1a J, Caballero D, Sureda A, Rubia JDL et al (2000) Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of efficacy and toxicity from the Spanish Registry for Transplantation in Multiple Myeloma. Br J Haematol 109(1):138\u2013147","journal-title":"Br J Haematol"},{"key":"5308_CR31","doi-asserted-by":"publisher","first-page":"204062072110129","DOI":"10.1177\/20406207211012985","volume":"12","author":"S Park","year":"2021","unstructured":"Park S, Shin DY, Hong J, Kim I, Koh Y, Byun JM, Yoon SS (2021) Busulfan plus melphalan versus melphalan alone conditioning regimen after bortezomib based triplet induction chemotherapy for patients with newly diagnosed multiple myeloma. Ther Adv Hematol 12:20406207211012985","journal-title":"Ther Adv Hematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05308-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05308-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05308-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T07:07:53Z","timestamp":1689232073000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05308-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,1]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["5308"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05308-0","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,1]]},"assertion":[{"value":"16 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the institutional ethics committees of participating institutions and was conducted in accordance with the Declaration of Helsinki. The institutional ethics committees waived the requirement for informed patient consent because of the retrospective study design.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interests"}}]}}